Amgen Offering Possible 6.61% Return Over the Next 38 Calendar Days

Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $105.00 short put and a strike $95.00 long put offers a potential 6.61% return on risk over the next 38 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $0.62 would be kept by the premium seller. The risk of $9.38 would be incurred if the stock dropped below the $95.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 42.6 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Tue, 12 Nov 2013 15:57:28 GMT
noodls – THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that …

InPlay: Amgen to highlight new evolocumab (AMG 145) data at upcoming american heart association scientific sessions 2013; first long-term data of a pcsk9 inhibitor to be featured in clinical science special reports session
Tue, 12 Nov 2013 14:03:25 GMT

Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Tue, 12 Nov 2013 14:00:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ — Amgen (AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, from the blood1, at the upcoming American Heart Association (AHA) Scientific Sessions 2013, being held Nov. 16 – 20 in Dallas. Data from the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against LDL-C Trial) study, which evaluates the safety, tolerability and sustained efficacy of long-term administration of evolocumab and standard of care in more than 1,100 patients with high cholesterol, will be featured during a Clinical Science: Special Reports session on Tuesday, Nov. 19, at 4:51 p.m. CST. “The Phase 2 OSLER study provides the first long-term 52-week data for a PCSK9 inhibitor in diverse patient populations with high cholesterol,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

The Street Can’t Help but Love Amgen
Tue, 12 Nov 2013 11:00:00 GMT
TheStreet – The company was never as bad as it was once perceived to be.

You’re not a genius so sell some stock right now
Sun, 10 Nov 2013 15:35:00 GMT
MarketWatch – And most important, the question is — what’s the “smart” thing do now? I work everyday to try to stay on top of when this bubble blowing bull market part of the cycle is going to end — and …

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.